The size of the North America Autoimmune Monoclonal Antibodies Market is expected to reach USD 13617.83 million by 2025 from USD 9069.01 million in 2020, growing at a CAGR of 8.47% during the forecast period 2020 to 2025.
Irregular functioning of humans’ immune system results in autoimmune disorders. Overproduction of self-reactive immune cells (such as antibodies & T-cells) damage regular functions of /cells/tissues/organs. This leads to different autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and other diseases. Typically, drugs are used as a treatment to cure autoimmune disorders. The adverse effects associated with drugs have made switched to concentrate on monoclonal antibodies.
Monoclonal antibodies have the ability to offer less toxic and more efficient therapeutic alternatives to treat autoimmune diseases. Recent years have seen the emergence of monoclonal antibodies being used to treat a wide array of diseases that are related to immune response. These antibodies are mono-specific comprising of identical immune cells which are clones of a single parent cell and are directed towards a specific cellular target. Thus monoclonal antibodies due to its customizable nature can be used to treat the self-reactive immune cells not impacting the normal ones.
A growing number of patients with autoimmune diseases, increasing research and development to promote the development of monoclonal antibodies, the presence of a large number of biotechnology companies, and rising demand for effective therapeutics are driving the growth of autoimmune monoclonal antibodies market in North America. In addition, increasing innovations in monoclonal antibodies research, rising number of product launches, and a growing number of collaborations & agreements to promote autoimmune therapies using monoclonal antibodies are further supporting the growth of autoimmune monoclonal antibodies market in North America.
However, stringent regulatory pathways and lack of proper reimbursement policies are expected to limit the growth of the autoimmune monoclonal antibodies market in North America.
This research report on the North America Autoimmune Monoclonal Antibodies Market has been segmented and sub-segmented into the following categories
By Source:
By Application:
By End-User:
By Country:
On the basis of source, the humanized segment is expected to command the largest share in North America Autoimmune Monoclonal Antibodies market, by the source in 2019.
On the basis of application, the rheumatoid arthritis application is anticipated to command the major share in North America Autoimmune Monoclonal Antibodies market, by application in 2019.
On the basis of end-user, the Hospitals/Clinics segment is expected to hold the major market share in North America Autoimmune Monoclonal Antibodies market, by application in 2016.
The key players dominating the North American Autoimmune Monoclonal Antibodies market include GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc.(U.S.), and UCB Company (Belgium).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Source
5.1.1 Murine
5.1.2 Chimeric
5.1.3 Humanized
5.1.4 Human
5.2 By Application
5.2.1 Systemic Lupus Erythematosus
5.2.2 Rheumatoid Arthritis
5.2.3 Multiple Sclerosis
5.2.4 Transplant Rejection/Graft Versus Host Disease
5.2.5 Others
5.3 End User
5.3.1 Hospitals/Clinics
5.3.2 Research Institute
5.3.3 Diagnostic Laboratories
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
7.5 Key Trends in Monoclonal Antibodies Development
7.5.1 Targeted Therapies
7.6 Promising Monoclonal Antibodies in Pipeline
7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 GlaxoSmithKline plc (U.K.)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 AstraZeneca plc (U.K.)
9.3 F. Hoffmann-La Roche Ltd. (Switzerland)
9.4 Bristol-Myers Squibb (U.S.)
9.5 Johnson & Johnson (U.S.)
9.6 Innovent Biologics, Inc. (China)
9.7 Takeda Pharmaceutical Company Ltd. (Japan)
9.8 Amgen Inc. (U.S.)
9.6 Innovent Biologics, Inc. (China)
9.10 UCB Company (Belgium)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
